RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Inclusion Criteria: * moderate to severe acute vulvovaginal candidiasis (severity score \>7) * positive potassium hydroxide wet preparation for pseudohyphae or budding yeast or positive Becton Dickinson Affirm test or positive vaginal culture for Candida species * vaginal pH \<4.5 for subjects with positive potassium hydroxide wet preparation * able to give written informed consent Exclusion Criteria: * receipt of intravaginal or systemic antifungal therapy within 7 days of randomization * known or suspected infectious causes of vulvovaginitis other than candidiasis * history of genital herpes * planned treatment or surgery during the study period for cervical intraepithelial neoplasia or cervical carcinoma * need for non-protocol systemic or vaginal antifungal therapy * history of hypersensitivity or allergic reaction to echinocandins, azoles, or their excipients * pregnant females * females who are breast feeding * women intending to become pregnant during the study period * recent use of an investigational medicinal product within 28 days or presence of an investigational device at the time of screening * subjects who use or anticipate use of intravaginal products * have any condition that the Investigator believes would put the subject at risk for participation or would confound the results of the study